Peptonic announced today that the company has signed an exclusive distribution agreement with FirstAid4All for the launch of its portfolio of self-care products in intimate women's health in the Benelux region. Peptonic's products will be sold under its own brand, VagiVital and Vernivia, enhancing brand identity and customer awareness of the company's offerings.

The agreement spans a three-year period with the possibility of extension. A first order ahead of the launch, worth approximately 0.5 MSEK, will be delivered this week. Other commercial terms remain confidential between the parties.

Terese Torenfält, Chief Operating Officer at Peptonic, expressed her enthusiasm about the agreement: "We are extremely excited about the collaboration with FirstAid4All and look forward to a close partnership. FirstAid4All is an established distributor in the self-care market and collaborates with several well-known Scandinavian companies. Their extensive network in the pharmacy market, coupled with their strong commitment, makes them an ideal partner."

For more information, please contact:

Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone:  +46 70-244 92 07

About Peptonic Medical AB                                                                                                   

Peptonic Medical AB (publ) is an innovative Swedish biomedical company engaged in the development and sales of clinically proven self-care treatments and self-diagnostic rapid tests in intimate women's health. The portfolio is sold under the brands Vagivital and Vernivia.

Peptonic Medical is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and rapid self-diagnostic tests in intimate women's health. Under the esteemed brands Vagivital and Vernivia, the portfolio delivers tangible solutions. The company's vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively.

The company continuously aims to broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio. Central to the growth strategy is the geographic expansion of VagiVital and Vernivia through local partners.